Mannkind Corporation (MNKD) 1.20 $MNKD
MannKind Announces Collaboration with JDRF
GlobeNewswire - Fri Jun 10, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that it has entered into a collaboration agreement with JDRF (formerly known as Juvenile Diabetes Research Foundation), the leading global organization funding type 1 diabetes research. The collaboration will combine JDRF's significant scientific and human resources with MannKind's active participation in the field of diabetes research and development in order to advance new treatments and therapies in areas of strategic alignment that can transform the lives of people with diabetes. A focus of the collaboration will be on the use of Afrezza(R), with its unique insulin delivery method, in the pediatric population.
MNKD: 1.20 (+0.02)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 83.25 (+0.80), SRPT: 17.39 (-0.02), BXLT: 46.02 (-0.18), MNKD: 1.20 (+0.02)
MannKind Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
GlobeNewswire - Mon May 09, 5:24PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the pricing of a registered direct public offering of up to 48,543,692 shares of common stock and warrants to purchase up to an aggregate of 48,543,692 shares of common stock to select institutional investors. Each share of common stock is being sold together with a warrant to purchase 0.75 of a share of common stock (A Warrants) and a warrant to purchase 0.25 of a share of common stock (B Warrants) for a combined purchase price of $1.03. The A Warrants will be exercisable at a price of $1.50 per share beginning upon issuance and will expire two years thereafter. The B Warrants will be exercisable at a price of $1.50 per share beginning in May 2017 and expire 18 months thereafter. The shares of common stock and the warrants will be immediately separable and will be issued separately. The offering is expected to close on or about May 12, 2016, subject to customary closing conditions.
MNKD: 1.20 (+0.02)
MannKind Corporation Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 3:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the first quarter ended March 31, 2016.
MNKD: 1.20 (+0.02)
MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 8:00 AM (PDT) at the Encore at Wynn Hotel in Las Vegas, Nevada.
MNKD: 1.20 (+0.02)
MannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016
GlobeNewswire - Mon May 02, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 first quarter financial results on Monday, May 9, 2016 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2016.
MNKD: 1.20 (+0.02)
Does Healthcare’s Past Predict its Future?
Michael Douglass and Kristine Harjes, The Motley Fool - Motley Fool - Sun May 01, 1:03PM CDT
It's time travel week at Industry Focus ! In this healthcare episode, Kristine Harjes brings on former host Michael Douglass to talk about how the healthcare industry has changed (and some areas it hasn't) since he left the show. Listen in to...
ANTM: 128.31 (-0.41), GILD: 83.25 (+0.80), MNKD: 1.20 (+0.02)
The Next Stock Warren Buffett May Sell
Matthew Frankel, Sean Williams, and Brian Feroldi, The Motley Fool - Motley Fool - Sun May 01, 12:09PM CDT
What stocks Warren Buffett is buying is a closely followed story by many investors. However, since he's known as a buy-and-hold investor, it's less common to hear someone ask "What is Buffett selling ?" However, Buffett does unload stocks from time...
T: 41.53 (+0.23), GM: 29.70 (+0.38), SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.91 (+0.06), CLDX: 4.49 (+0.04), XON: 25.02 (+0.37), MNKD: 1.20 (+0.02)
3 Healthcare Stocks We Won't Buy
Brian Feroldi, Keith Speights, and Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 19, 3:22PM CDT
PHOTO CREDIT: BRYAN ROSENGRANT ON FLICKR. Did you know that roughly 10,000 baby boomers will turn 65 every day for the next 13 years? It's true, and that fact should be a boon to the healthcare sector, in general, as spending on staying healthy...
VRX: 21.92 (+0.28), LLY: 73.50 (+0.43), MNKD: 1.20 (+0.02)
Analyst Call Rescheduled to April 26, 2016
GlobeNewswire - Tue Apr 19, 12:26PM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) has postponed its analyst call scheduled for today, April 19, 2016, due to the unavailability of its Chief Executive Officer, Matthew J. Pfeffer. Mr. Pfeffer was diagnosed overnight with a retinal detachment, and is undergoing emergency surgery this morning to correct the condition.
MNKD: 1.20 (+0.02)
MannKind Expands Commercial Capabilities With Two New Hires
GlobeNewswire - Tue Apr 19, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced two senior appointments to its commercial organization. Joining the Company are Joseph Saldanha as Vice President of Marketing and Agustin (Tino) Quintero as Vice President of Market Value, Access and Trade. Both will report to Michael Castagna, MannKind's Chief Commercial Officer.
MNKD: 1.20 (+0.02)
Better Buy: MannKind Corporation vs. Sanofi
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 14, 9:03AM CDT
Image source: Bill Brooks via Flickr Creative Commons. It's been a rough couple of years to be an investor in both Sanofi and MannKind . Both companies have faced their own set of unique challenges that have caused their shares to drastically...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02), REGN: 356.09 (+4.17)
Why MannKind Corporation Shares Are Soaring 14% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 11:44AM CDT
IMAGE SOURCE: MANNKIND CORPORATION. What: A week before its planned investor conference on April 19 to explain its commercialization strategy for Afrezza, shares of MannKind Corporation are skyrocketing 13.7% at 12:00 p.m. ET today. So...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Hertz Global Holdings Inc Slumps and MannKind Corporation Soars as Stocks Drop
Demitrios Kalogeropoulos, The Motley Fool - Motley Fool - Mon Apr 11, 4:35PM CDT
Stocks stumbled into the start of earnings season on Monday, with early gains evaporating by the end of the trading session. Despite opening higher by almost 1%, the Dow Jones Industrial Average had lost 21 points, or 0.1%, by the closing bell....
HTZ: 11.56 (+0.22), SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
MannKind Corporation Is Skyrocketing Today, and Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Mon Apr 11, 11:23AM CDT
IMAGE SOURCE: MANNKIND. What: Shares of MannKind Corporation , a biopharmaceutical company primarily focused on treating diabetes, are up more than 20% as of 10:30 a.m. ET on huge volume after the company announced that it will be holding a...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 3.83 (+0.03), CANF: 2.71 (+0.04), OMEX: 2.25 (unch), MNKD: 1.20 (+0.02)
MannKind to Discuss U.S. Commercialization Update for Afrezza(R)
GlobeNewswire - Mon Apr 11, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host an analyst call for the investment community to learn about the company's general commercialization strategy in the US for Afrezza(R) (insulin human) Inhalation Powder. MannKind has recently assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi and will begin to distribute Afrezza in the third quarter. Until that time, Sanofi will continue to distribute Afrezza from its existing inventory of product.
MNKD: 1.20 (+0.02)
MannKind Regains Afrezza(R) Marketing Rights
GlobeNewswire - Tue Apr 05, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) has assumed responsibility for the worldwide development and commercialization of Afrezza (insulin human) Inhalation Powder from Sanofi, effective today, in a transition that ensures patients will not experience any interruption in their treatment. Under terms of the transfer agreement, Sanofi will continue to distribute Afrezza from its existing inventory until MannKind begins to distribute Afrezza during the third quarter.
MNKD: 1.20 (+0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.38 (+0.44), CMRX: 3.69 (-0.04), GERN: 2.69 (+0.02), CYTX: 2.00 (-0.01), CLDX: 4.49 (+0.04), SGMO: 5.70 (+0.08), PTCT: 6.73 (+0.13), ATHX: 2.04 (+0.09), MNKD: 1.20 (+0.02)
MannKind Announces Collaboration with JDRF
GlobeNewswire - Fri Jun 10, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that it has entered into a collaboration agreement with JDRF (formerly known as Juvenile Diabetes Research Foundation), the leading global organization funding type 1 diabetes research. The collaboration will combine JDRF's significant scientific and human resources with MannKind's active participation in the field of diabetes research and development in order to advance new treatments and therapies in areas of strategic alignment that can transform the lives of people with diabetes. A focus of the collaboration will be on the use of Afrezza(R), with its unique insulin delivery method, in the pediatric population.
MNKD: 1.20 (+0.02)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 83.25 (+0.80), SRPT: 17.39 (-0.02), BXLT: 46.02 (-0.18), MNKD: 1.20 (+0.02)
MannKind Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
GlobeNewswire - Mon May 09, 5:24PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the pricing of a registered direct public offering of up to 48,543,692 shares of common stock and warrants to purchase up to an aggregate of 48,543,692 shares of common stock to select institutional investors. Each share of common stock is being sold together with a warrant to purchase 0.75 of a share of common stock (A Warrants) and a warrant to purchase 0.25 of a share of common stock (B Warrants) for a combined purchase price of $1.03. The A Warrants will be exercisable at a price of $1.50 per share beginning upon issuance and will expire two years thereafter. The B Warrants will be exercisable at a price of $1.50 per share beginning in May 2017 and expire 18 months thereafter. The shares of common stock and the warrants will be immediately separable and will be issued separately. The offering is expected to close on or about May 12, 2016, subject to customary closing conditions.
MNKD: 1.20 (+0.02)
MannKind Corporation Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 3:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the first quarter ended March 31, 2016.
MNKD: 1.20 (+0.02)
MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 8:00 AM (PDT) at the Encore at Wynn Hotel in Las Vegas, Nevada.
MNKD: 1.20 (+0.02)
MannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016
GlobeNewswire - Mon May 02, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 first quarter financial results on Monday, May 9, 2016 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2016.
MNKD: 1.20 (+0.02)
Does Healthcare’s Past Predict its Future?
Michael Douglass and Kristine Harjes, The Motley Fool - Motley Fool - Sun May 01, 1:03PM CDT
It's time travel week at Industry Focus ! In this healthcare episode, Kristine Harjes brings on former host Michael Douglass to talk about how the healthcare industry has changed (and some areas it hasn't) since he left the show. Listen in to...
ANTM: 128.31 (-0.41), GILD: 83.25 (+0.80), MNKD: 1.20 (+0.02)
The Next Stock Warren Buffett May Sell
Matthew Frankel, Sean Williams, and Brian Feroldi, The Motley Fool - Motley Fool - Sun May 01, 12:09PM CDT
What stocks Warren Buffett is buying is a closely followed story by many investors. However, since he's known as a buy-and-hold investor, it's less common to hear someone ask "What is Buffett selling ?" However, Buffett does unload stocks from time...
T: 41.53 (+0.23), GM: 29.70 (+0.38), SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.91 (+0.06), CLDX: 4.49 (+0.04), XON: 25.02 (+0.37), MNKD: 1.20 (+0.02)
3 Healthcare Stocks We Won't Buy
Brian Feroldi, Keith Speights, and Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 19, 3:22PM CDT
PHOTO CREDIT: BRYAN ROSENGRANT ON FLICKR. Did you know that roughly 10,000 baby boomers will turn 65 every day for the next 13 years? It's true, and that fact should be a boon to the healthcare sector, in general, as spending on staying healthy...
VRX: 21.92 (+0.28), LLY: 73.50 (+0.43), MNKD: 1.20 (+0.02)
Analyst Call Rescheduled to April 26, 2016
GlobeNewswire - Tue Apr 19, 12:26PM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) has postponed its analyst call scheduled for today, April 19, 2016, due to the unavailability of its Chief Executive Officer, Matthew J. Pfeffer. Mr. Pfeffer was diagnosed overnight with a retinal detachment, and is undergoing emergency surgery this morning to correct the condition.
MNKD: 1.20 (+0.02)
MannKind Expands Commercial Capabilities With Two New Hires
GlobeNewswire - Tue Apr 19, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced two senior appointments to its commercial organization. Joining the Company are Joseph Saldanha as Vice President of Marketing and Agustin (Tino) Quintero as Vice President of Market Value, Access and Trade. Both will report to Michael Castagna, MannKind's Chief Commercial Officer.
MNKD: 1.20 (+0.02)
Better Buy: MannKind Corporation vs. Sanofi
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 14, 9:03AM CDT
Image source: Bill Brooks via Flickr Creative Commons. It's been a rough couple of years to be an investor in both Sanofi and MannKind . Both companies have faced their own set of unique challenges that have caused their shares to drastically...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02), REGN: 356.09 (+4.17)
Why MannKind Corporation Shares Are Soaring 14% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 11:44AM CDT
IMAGE SOURCE: MANNKIND CORPORATION. What: A week before its planned investor conference on April 19 to explain its commercialization strategy for Afrezza, shares of MannKind Corporation are skyrocketing 13.7% at 12:00 p.m. ET today. So...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Hertz Global Holdings Inc Slumps and MannKind Corporation Soars as Stocks Drop
Demitrios Kalogeropoulos, The Motley Fool - Motley Fool - Mon Apr 11, 4:35PM CDT
Stocks stumbled into the start of earnings season on Monday, with early gains evaporating by the end of the trading session. Despite opening higher by almost 1%, the Dow Jones Industrial Average had lost 21 points, or 0.1%, by the closing bell....
HTZ: 11.56 (+0.22), SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
MannKind Corporation Is Skyrocketing Today, and Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Mon Apr 11, 11:23AM CDT
IMAGE SOURCE: MANNKIND. What: Shares of MannKind Corporation , a biopharmaceutical company primarily focused on treating diabetes, are up more than 20% as of 10:30 a.m. ET on huge volume after the company announced that it will be holding a...
SNY: 40.72 (+0.43), MNKD: 1.20 (+0.02)
Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 3.83 (+0.03), CANF: 2.71 (+0.04), OMEX: 2.25 (unch), MNKD: 1.20 (+0.02)
MannKind to Discuss U.S. Commercialization Update for Afrezza(R)
GlobeNewswire - Mon Apr 11, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host an analyst call for the investment community to learn about the company's general commercialization strategy in the US for Afrezza(R) (insulin human) Inhalation Powder. MannKind has recently assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi and will begin to distribute Afrezza in the third quarter. Until that time, Sanofi will continue to distribute Afrezza from its existing inventory of product.
MNKD: 1.20 (+0.02)
MannKind Regains Afrezza(R) Marketing Rights
GlobeNewswire - Tue Apr 05, 8:00AM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) has assumed responsibility for the worldwide development and commercialization of Afrezza (insulin human) Inhalation Powder from Sanofi, effective today, in a transition that ensures patients will not experience any interruption in their treatment. Under terms of the transfer agreement, Sanofi will continue to distribute Afrezza from its existing inventory until MannKind begins to distribute Afrezza during the third quarter.
MNKD: 1.20 (+0.02)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.38 (+0.44), CMRX: 3.69 (-0.04), GERN: 2.69 (+0.02), CYTX: 2.00 (-0.01), CLDX: 4.49 (+0.04), SGMO: 5.70 (+0.08), PTCT: 6.73 (+0.13), ATHX: 2.04 (+0.09), MNKD: 1.20 (+0.02)
